Regorafenib
RET Fusion Positive Cancer
University of California, San FranciscoSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the RET Fusion Positive Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Guangdong Provincial People's Hospital | Phase 2 | CCC |
Ceritinib University of California, San Francisco | Phase 2 | CCC |
Toripalimab Guangdong Provincial People's Hospital | Phase 2 | CCC |
Entrectinib University of California, San Francisco | Phase 2 | CCC |
Pralsetinib, Trans- Fudan University | Phase 1/2 | CCC |
View all 13 →
Same molecule, other indications
Regorafenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →